Get the Stockscreener App
1.46
0.69%
0.01
After Hours:
1.48
0.02
+1.37%
MAIA Biotechnology Inc stock is traded at $1.46, with a volume of 553.51K.
It is up +0.69% in the last 24 hours and up +7.35% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.45
Open:
$1.48
24h Volume:
553.51K
Relative Volume:
0.73
Market Cap:
$88.77M
Revenue:
-
Net Income/Loss:
$-24.25M
P/E Ratio:
-2.1483
EPS:
-0.6796
Net Cash Flow:
$-19.95M
1W Performance:
-1.35%
1M Performance:
+7.35%
6M Performance:
-4.58%
1Y Performance:
-21.08%
1-Day Range:
$1.45
$1.505
1-Week Range:
$1.395
$1.51
52-Week Range:
$0.87
$3.19
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.46 | 87.55M | 0 | -24.25M | -19.95M | -0.6796 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
MAIA Q1 2026 Earnings: Narrower Loss Beats Expectations as Clinical Pipeline AdvancesRevenue Report - dars.gov.et
MAIA Biotechnology, Inc. Actuals & Estimates (AMEX:MAIA) - TradingView
MAIA Biotechnology, Inc. Actuals & Estimates (BOATS:MAIA) - TradingView
Why Is MAIA Biotechnology (NYSE:MAIA) Tracking Higher on Trial News? - Kalkine Media
MAIA Forecast — Price Target — Prediction for 2027 - TradingView
MAIA finishes THIO-101 enrollment abroad, with 41 lung cancer patients treated - Stock Titan
Why Gold Prices Are CrashingACT NOW! Vincenzo Italiano (pm3QIbzhx7) - Fathom Journal
Noble Financial Maintains MAIA Biotechnology(MAIA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
MAIA Should I Buy - Intellectia AI
Maia Biotechnology Inc (MAIA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MAIA Gains on Setting up New Site - Baystreet.ca
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion - GlobeNewswire
Maia Biotechnology Inc (MAIA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maia Biotechnology Inc (MAIA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Maia Biotechnology Inc (MAIA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Maia Biotechnology Inc (MAIA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Maia Biotechnology Inc (MAIA) Institutional Confidence - TradingKey
Maia Biotechnology Inc (MAIA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Maia Biotechnology Inc (MAIA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maia Biotechnology Inc (MAIA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MAIA Biotechnology Surges 4.6%, Approaches Key Resistance at $1.43MESA MA - newsline.com
MAIA Biotechnology Holds Steady at $1.30, Consolidating Between Support and ResistanceETF Creation Redemption - newsline.com
MAIA Biotechnology (MAIA) Holds Steady at $1.30 as Consolidation Phase EmergesStock News - newsline.com
MAIA Biotechnology Activates Second US Site for Phase 2 Trial of Lung Cancer Treatment - Moomoo
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial - The Manila Times
MAIA Biotechnology Activates and Opens Enrollment at Second - GlobeNewswire
MAIA Q1 2026 Earnings: EPS Beat on Lower Net Loss, Focus on Clinical PipelineConsensus Beat Rate - newsline.com
MAIA Biotechnology Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEPS Consistency Score - newsline.com
MAIA Biotechnology Inc. (MAIA) announced that its pivotal Phase III clinical trial for non-small cell lung cancer is showing strong momentum in patient enrollment and dosing. - Bitget
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial - The Manila Times
MAIA Biotechnology Reports Patient Enrollment Progress in Phase 3 Trial of Telomere-Targeting Therapy for Advanced Non-Small Cell Lung Cancer - Quiver Quantitative
Lung cancer trial drug saw 17.8-month survival vs 5.8 on chemo in MAIA study - Stock Titan
MAIA Biotechnology Reports Strong Enrollment and Dosing - GlobeNewswire
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion - The Manila Times
FDA clears U.S. trial of MAIA lung cancer drug for third-line patients - Stock Titan
Top MAIA Biotechnology Insiders Make Bold Moves With Fresh Stock Purchases - TipRanks
Maia Biotechnology CSO Sergei Gryaznov buys $2,690 in common stock By Investing.com - Investing.com Canada
MAIA Biotechnology Announces Open Market Purchases by CEO and Director - The Manila Times
MAIA Biotechnology Executives Increase Stock Holdings, Express Confidence in Cancer Immunotherapy Development - Quiver Quantitative
Maia Biotechnology director Stan Smith buys $100,200 in company stock By Investing.com - Investing.com Australia
Maia Biotechnology CEO Vlad Vitoc buys $100,885 in company stock - Investing.com UK
Maia Biotechnology CSO Sergei Gryaznov buys $2,690 in common stock - Investing.com
Maia Biotechnology director Stan Smith buys $100,200 in company stock - Investing.com
Maia Biotechnology CEO Vlad Vitoc buys $100,885 in company stock By Investing.com - Investing.com India
MAIA Biotechnology (MAIA) CEO Vitoc Vlad adds 72,700 shares in open-market buy - Stock Titan
Director Stan Smith adds 75,000 MAIA (NASDAQ: MAIA) shares via trust purchase - Stock Titan
MAIA (MAIA) Chief Scientific Officer purchases 2,000 company shares in market trade - Stock Titan
MAIA (MAIA) CEO awarded 800,000 stock options at $1.39 exercise price - Stock Titan
MAIA Biotechnology (MAIA) grants CSO 400,000 stock options at $1.39 - Stock Titan
MAIA Biotechnology (MAIA) grants 60,000 stock options to head of finance - Stock Titan
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology - The Manila Times
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
MAIA Biotechnology Inc Stock (MAIA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smith Stan | Director |
Jun 01 '26 |
Buy |
1.34 |
75,000 |
100,200 |
1,519,178 |
| Gryaznov Sergei | Chief Scientific Officer |
Jun 01 '26 |
Buy |
1.34 |
2,000 |
2,690 |
46,511 |
| Smith Stan | Director |
Dec 22 '25 |
Buy |
1.22 |
57,189 |
69,999 |
1,421,478 |
| CHAOUKI STEVEN M | Director |
Dec 22 '25 |
Buy |
1.22 |
40,849 |
49,999 |
151,873 |
| Louie Ngar Yee | Director |
Dec 22 '25 |
Buy |
1.22 |
81,699 |
100,000 |
1,248,888 |
| Smith Stan | Director |
Dec 05 '25 |
Buy |
1.20 |
13,740 |
16,441 |
4,580 |
| Vitoc Vlad | Chief Executive Officer |
Nov 28 '25 |
Buy |
1.14 |
50,000 |
56,830 |
881,421 |
| Vitoc Vlad | Chief Executive Officer |
Nov 26 '25 |
Buy |
1.05 |
22,000 |
23,019 |
853,421 |
| Luput Cristian | Director |
Nov 26 '25 |
Buy |
1.08 |
20,000 |
21,616 |
419,483 |
| Luput Cristian | Director |
Nov 28 '25 |
Buy |
1.11 |
18,145 |
20,230 |
437,628 |
0.05%
0.74%
Cap:
|
Volume (24h):